RxDoctor Payments DataLook up a doctor →

Andrew Bartlett, DO

Internal Medicine · Champaign, ILNPI 1073520516

Payments from drug & device makers

$4,085,869in general payments, 2019–2025

Across 1,604 payments — averaging $2547.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$1.9M
  • Emergent Biosolutions Inc.$1.3M
  • Johnson & Johnson$405K
  • Regeneron$275K
  • GSK$153K
  • Pfizer$84K
  • plus $93 from 4 others

What the payments were for

  • Food & beverage$6266%
  • Education$3234%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.91$1,904,035
Emergent Biosolutions Inc.1,350$1,265,458
Johnson & Johnson23$404,535
Regeneron46$274,891
GSK26$152,783
Pfizer63$84,073
Lilly USA, LLC2$33
AbbVie1$32
Novo Nordisk1$16
Novartis1$12

How this compares

$4,085,869 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$168,054
Medicare patients
282
Services billed
21,368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin225$246,855
EliquisApixaban126$139,111
OzempicSemaglutide118$127,597
JanuviaSitagliptin Phosphate49$55,524
XareltoRivaroxaban33$41,192
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$29,821
TrulicityDulaglutide19$20,422
MounjaroTirzepatide18$18,928
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen486$16,908
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$15,718
LinzessLinaclotide18$14,682
Atorvastatin Calcium840$10,545
Repatha SureclickEvolocumab13$8,265
Verapamil SrVerapamil Hcl35$7,342
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$6,642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$84,073$144,217143 claims
Novo NordiskOzempic$16$127,597118 claims
Johnson & JohnsonXarelto$404,535$41,19233 claims
Lilly USA, LLCTrulicity, Mounjaro$33$39,35037 claims
AbbVieLinzess, Creon$32$19,21930 claims
GSKTrelegy Ellipta$152,783$15,71826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Champaign

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →